MK-4409

MK-4409

Clinical data
ATC code	None
Legal status
Legal status	Investigational New Drug
Identifiers
IUPAC name 2-[5-[5-(5-chloropyridin-2-yl)sulfanyl-2-(4-fluorophenyl)-1,3-oxazol-4-yl]pyridin-2-yl]propan-2-ol
PubChem (CID)	53341130
ChemSpider	25069631
ChEMBL	CHEMBL1812717
Chemical and physical data
Formula	C22H17FN3O2S
Molar mass	441.905 g/mol
3D model (Jmol)	Interactive image
SMILES c3nc(C(O)(C)C)ccc3-c1nc(-c4ccc(F)cc4)oc1Sc(nc2)ccc2Cl
InChI InChI=1S/C22H17ClFN3O2S/c1-22(2,28)17-9-5-14(11-25-17)19-21(30-18-10-6-15(23)12-26-18)29-20(27-19)13-3-7-16(24)8-4-13/h3-12,28H,1-2H3 Key:DBZMCSVIITXLCC-UHFFFAOYSA-N

MK-4409 is a drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC₅₀ of 11nM, and both analgesic and antiinflammatory effects in animal studies. It was developed for the treatment of neuropathic pain and has progressed as far as early stage human clinical trials.^[1][2]

See also

• LY-2183240
• URB-597
• PF-3845
• BIA 10-2474

References

1. Chobanian; et al. (10 April 2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Med. Chem. Lett.
2. Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.